Although the expression of the putative cannabinoid receptor GPR55 has been shown to be involved in the growth of various tumours and is increased in a number of cancers, its expression has not been examined in patients with endometrial cancer (EC). Quantitative RT-PCR (for mRNA levels) and immunohistochemistry (for protein levels) were used to measure GPR55 expression in patients with Type 1 and Type 2 EC and correlated against cannabinoid receptor (CB1 and CB2) protein levels using non-cancerous endometrium as the control tissue. The data indicated that GPR55 transcript and GPR55 protein levels were significantly (p < 0.002 and p < 0.0001, respectively) higher in EC tissues than in control tissues. The levels of immunoreactive GPR55 protein were correlated with GPR55 transcript levels, but not with the expression of CB1 receptor protein, and were inversely correlated with CB2 protein expression, which was significantly decreased. It can be concluded that GPR55 expression is elevated in women with EC, and thus could provide a potential novel biomarker and therapeutic target for this disease.

尽管推定的大麻素受体 GPR55 的表达已被证明与各种肿瘤的生长有关，并且在许多癌症中有所增加，但尚未在子宫内膜癌 (EC) 患者中检查其表达。定量 RT-PCR（用于 mRNA 水平）和免疫组织化学（用于蛋白质水平）用于测量 1 型和 2 型 EC 患者的 GPR55 表达，并使用非癌性子宫内膜作为与大麻素受体（CB1 和 CB2）蛋白水平相关联控制组织。数据表明 GPR55 转录本和 GPR55 蛋白水平显着（p  < 0.002 和p < 0.0001，分别）在 EC 组织中高于对照组织。免疫反应性GPR55蛋白水平与GPR55转录水平相关，但与CB1受体蛋白表达无关，与CB2蛋白表达呈负相关，显着降低。可以得出结论，患有 EC 的女性 GPR55 表达升高，因此可以为这种疾病提供潜在的新型生物标志物和治疗靶点。